For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Granisetron in the prevention of irradiation-induced emesis.
A double-blind double-dummy , comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate , single fraction total body irradiation prior to bone marrow transplantation . Patients were r and omised into one of two groups , receiving either granisetron , a specific 5-HT3 antagonist or a combination of metoclopramide , dexamethasone phosphate and lorazepam to assess the comparative efficacy of the two regimens in the control of irradiation-induced nausea and vomiting . After 24 h eight patient ( 53 % ) treated with granisetron showed a complete response compared with two patients ( 13 % ) in the comparator group . The control of vomiting by granisetron , over both 24 h and 7-day periods ( P = 0.001 and P = 0.004 ) , was significantly better than that seen with the comparator and required significantly fewer rescue doses . The safety profiles in the two groups appeared similar , with the exception that granisetron produced less drowsiness than the comparator
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .